( .com . About Genta Genta Incorporat...)Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO,Health

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

    -- the Company's ability to obtain necessary regulatory approval for

       Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

       European Medicines Agency ("EMEA");

    -- the safety and efficacy of the Company's products or product

       candidates;

    -- the Company's assessment of its clinical trials;

    -- the commencement and completion of clinical trials;

    -- the Company's ability to develop, manufacture, license and sell its

     
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal
Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery